David E. I. Pyott

President at International Council of Ophthalmology Foundation

David E. I. Pyott

David E. I. Pyott

President at International Council of Ophthalmology Foundation

Overview

Career Highlights

International Council of Ophthalmology Foundation
Allergan Sales LLC
Allergan Specialty Therapeutics, Inc.

RelSci Relationships

4232

Number of Boards

34

Birthday

1954

Age

67

Number of Awards

6

Contact Data

Trying to get in touch with David E. I. Pyott? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!

Relationships

View Relationship Details

RelSci Relationships are individuals David E. I. Pyott likely has professional access to. A relationship does not necessarily indicate a personal connection.

James M. Hindman

Former Chief Financial Officer at Allergan Specialty Therapeutics, Inc.

Relationship likelihood: Strong

Al Sommer

Dean Emeritus at Johns Hopkins Bloomberg School of Public Health

Relationship likelihood: Strong

Douglas S. Ingram

President & Chief Executive Officer at Sarepta Therapeutics, Inc.

Relationship likelihood: Strong

Brent Saunders

Chairman, President & Chief Executive Officer at The Allergan Foundation

Relationship likelihood: Strong

Jeffrey L. Edwards

Former Executive Vice President, Finance & Business Development & Chief Financial Officer at Allergan, Inc.

Relationship likelihood: Strong

Timothy R. G. Sear

Former President & Chief Executive Officer at Alcon, Inc.

Relationship likelihood: Strong

John Maraganore

Chief Executive Officer at Alnylam Pharmaceuticals, Inc.

Relationship likelihood: Strong

Adrienne Graves

Director at Glaucoma Research Foundation

Relationship likelihood: Strong

Dean A. Scarborough

Former Chief Executive Officer at Avery Dennison Corporation

Relationship likelihood: Strong

Mitch Butier

Chairman of the Board, President & Chief Executive Officer at Avery Dennison Corporation

Relationship likelihood: Strong

Reveal deeper insights into your organization's relationships
with RelSci Contact Aggregator.

Empower Your Business Applications with Industry-Leading
Relationship Data from the RelSci API.

Get Contact Information on the
World's Most Influential Decision Makers.

Discover the Power of Your Network with
RelSci Premium Products.

In The News

RelSci

January 15, 2021

David E. I. Pyott is now serving in a new board position at Pliant Therapeutics, Inc.

GlobeNewswire

January 12, 2021

Pliant Therapeutics Announces Appointment of David Pyott to Board of Directors

RelSci

September 8, 2020

David E. I. Pyott purchased $1M worth of shares in BioMarin Pharmaceutical, Inc. in August 2020

Nasdaq

September 2, 2020

Wednesday 9/2 Insider Buying Report: IMBI, BMRN

Business Wire

February 28, 2020

Avery Dennison Announces Change in Board Leadership Structure

Paths to David E. I. Pyott

Potential Connections via
Relationship Science

You

David E. I. Pyott

President at International Council of Ophthalmology Foundation

Education

Master of Arts

The University of Edinburgh

The University of Edinburgh, founded in 1583, is a public research university in Edinburgh, the capital of Scotland. It was the fourth university to be established in Scotland and the sixth in the United Kingdom, and is one of the most prestigious universities in the world. Edinburgh receives approximately 47,000 applications every year, making it the third most popular university in the UK by volume of applicants. Entrance is intensely competitive, with offer chances of 27% in the 2010-2011 admissions cycle. The university is deeply embedded in the fabric of the city, with many of the buildings in the historic Old Town belonging to the university.

Diploma in International & European Law

University of Amsterdam

The University of Amsterdam is one of the world’s intellectual hubs with a rich history dating back to 1632

Career History

President & Chief Executive Officer

1998 - 2015

Allergan, Inc.

Allergan, Inc. operated as a global healthcare company. It engaged in the development and commercialization of specialty pharmaceutical, medical device ,and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, obesity intervention, urological, and other specialty markets. The company was founded by Gavin S. Herbert in 1950 and headquartered in Irvine, CA.

President & Chief Executive Officer

1992 - 1995

Sandoz Nutrition Corp.

General Manager

Prior

Sandoz Nutrition SA

Boards & Committees

Independent Director

2021 - Current

Pliant Therapeutics, Inc.

Pliant Therapeutics, Inc. engages in the business of developing and commercializing novel therapies for fibrotic diseases. It offers product discovery engine. The company is pursuing drug development programs for a range of fibrotic diseases, focusing on tissue-specific integrin modulation and TGF-ß1 signaling inhibition. Pliant Therapeutics was founded by Bradley Backes, Bill De Grado, Hal Chapman, and Dean Sheppard in June 2015 and is headquartered in South San Francisco, CA.

Chairman, Board of Directors

2016 - Current

Bioniz Therapeutics, Inc.

Bioniz Therapeutics, Inc. operates as a biopharmaceutical firm. The firm engages in the development of peptide therapeutics that selectively and simultaneously inhibit multiple cytokines for the treatment of immune diseases and cancer. The company was founded by Yutaka Tagaya and Nazli Azimi in 2009 and is headquartered in Irvine, CA.

Member, Board of Directors

2016 - Current

BioMarin Pharmaceutical, Inc.

About BioMarin BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; KUVAN® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse™ (amifampridine phosphate), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Product candidates include GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase III clinical development for the treatment of MPS IVA, PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU, BMN-701, a novel fusion protein of insulin-like growth factor 2 and acid alpha glucosidase (IGF2-GAA), which is currently in Phase I/II clinical development for the treatment of Pompe disease, and BMN-673, a poly ADP-ribose polymerase (PARP) inhibitor, which is currently in Phase I/II clinical development for the treatment of genetically-defined cancers and BMN-111, a modified C-natriuretic peptide, which is currently in Phase I clinical development for the treatment of achondroplasia.

Trustee

2019 - Current

California Institute of Technology

California Institute of Technology provides education focusing on science, engineering, academia, business, and public service. The company was founded in 1891 and it is headquartered in Pasadena, CA.

Member of the Governing Board

2015 - Current

University of London - London Business School

London Business School (LBS) is an international business school and a constituent college of the federal University of London, located in central London, England, United Kingdom, beside Regent's Park. It was established in 1964, after the Franks Report recommended the establishment of two business schools, as part of existing universities (London Business School and Manchester Business School), but with considerable autonomy.

Member, Advisory Board

2002 - Current

American Academy of Ophthalmology Foundation

Non-Profit Donations & Grants

Learn how non-profit organizations benefit from RelSci

$1,000 - $4,999

2016

Glaucoma Research Foundation

Glaucoma Research Foundation is a nonprofit company headquartered in San Francisco, CA. The firm provides education services. It was founded by Adrienne L. Graves. Thomas M. Brunner is the current CEO of the firm.The company says this about itself: Glaucoma Research Foundation (GRF) is a national non-profit organization dedicated to finding a cure for glaucoma. For more than 40 years, Glaucoma Research Foundation has worked to advance sight-saving research and provide essential educational resources for patients. It funds critical research into glaucoma treatment, vision restoration, and a cure for glaucoma. It is also the leading source of information for glaucoma patients and their families.

$10K - $25K

2010

International Council of Ophthalmology Foundation

THE ORGANIZATION IS DEDICATED TO THE SUPPORT OF PROGRAMS THAT WILL ELEVATE THE LEVEL OF OPHTHALMIC EDUCATION WORLDWIDE.

$5,000 - $10K

2010

Foundation of The American Academy of Ophthalmology

TO ADVANCE AAO'S PRIORITY PROGRAMS IN EDUCATION, QUALITY AND DATA SCIENCE, AND PUBLIC SERVICE.

Political Donations

$10K

2015

John Boehner

Director at Acreage Holdings

$10K

2014

John Boehner

Director at Acreage Holdings

$2,000

2014

Mimi Walters

Former Representative at Office of the Representative from California's 45th District, Mimi Walters

Transactions

Details Hidden

Apollo Endosurgery, Inc. (Inactive), CPMG, PTV Sciences LP, Novo Ventures 1 A/S, H.I.G. BioHealth Partners LLC purchase Allergan, Inc. /Obesity Intervention Business from Allergan, Inc.

Investments

Details Hidden

Mellon Medical BV

Mellon Medical BV manufactures and develops surgical suturing devices. The firm’s suturing device, the Switch, is designed for surgeons who perform the challenging operations and can easily be rotated in the hand because of its pencil-like shape. The company was founded in April 2013 by Mark Vrancken Peeters and is headquartered in Nijmegen, the Netherlands.

Details Hidden

Sienna Biopharmaceuticals, Inc.

Sienna Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that focuses on the discovery, clinical development, and commercialization of aesthetics and medical dermatology. Its products include Topical by Design platform for patients with inflammatory skin diseases and other dermatologic and aesthetic conditions through SNA-120, SNA-125, and SNA-001. The company was founded by Todd Harris and Frederick C. Beddingfield III on July 27, 2010 and is headquartered in Westlake Village, CA.

Details Hidden

Bioniz Therapeutics, Inc.

Bioniz Therapeutics, Inc. operates as a biopharmaceutical firm. The firm engages in the development of peptide therapeutics that selectively and simultaneously inhibit multiple cytokines for the treatment of immune diseases and cancer. The company was founded by Yutaka Tagaya and Nazli Azimi in 2009 and is headquartered in Irvine, CA.

Public Holdings

Restricted data only for RelSci Professional users.

Awards & Honors

Rank #80

2014

Chief Executive Magazine - Wealth Creators

Rank #45

2014

Fortune Magazine - Business Person of the Year

Rank #4

2014

Harvard Business Review - 100 Best-Performing CEOs in the World

Events

Attendee

Washington, DC, United States

2010 Wall Street Journal CEO Council Annual Meeting

Wall Street Journal’s annual CEO Council meeting released specific priorities that both government and business must address to restore global growth and to increase public confidence in business. The plans voted by CEO Council members as the top two priorities each focused on job creation – leading with a call to foster global trade, followed by a call for the president to encourage a competitive business environment and be an advocate for business in general. The CEO Council worked together in task force sessions charged with identifying and ranking the most urgent priorities. Leading subject-matter experts provided key perspectives and information for the discussion, which focused on five key topics: fresh approaches to energy and the environment, the future of global finance, creating sustainable jobs, restoring confidence in business and next step for healthcare.

Other Affiliations

David E. I. Pyott is affiliated with Allergan, Inc., Sandoz Nutrition Corp., Sandoz Nutrition SA, Serica Technologies, Inc., Vicept Therapeutics, Inc., Allergan Specialty Therapeutics, Inc., SkinMedica, Inc., The Allergan Foundation, Edwards Lifesciences LLC, Novartis AG, International Council of Ophthalmology Foundation, Sienna Biopharmaceuticals, Inc., Avery Dennison Corporation, Allergan Sales LLC, Pliant Therapeutics, Inc., Bioniz Therapeutics, Inc., BioMarin Pharmaceutical, Inc., Alnylam Pharmaceuticals, Inc., Koninklijke Philips NV, SVB Leerink LLC, Sienna Biopharmaceuticals, Inc., Alliance for Eye & Vision Research, Allergan, Inc., Serica Technologies, Inc., Edwards Lifesciences Corp., Avery Dennison Corporation, Novartis AG, Pacific Mutual Holding Company, Pacific LifeCorp., Rani Therapeutics LLC, MAP Pharmaceuticals, Inc., Allergan Sales LLC, Philips Electronics North America Corporation, California Institute of Technology, University of London - London Business School, American Academy of Ophthalmology Foundation, Foundation of The American Academy of Ophthalmology, The David & Julianna Pyott Foundation, The International Council of Ophthalmology, International Council of Ophthalmology Foundation, Biotechnology Innovation Organization, American Academy of Ophthalmology, Glaucoma Research Foundation, Pan-American Ophthalmological Foundation, The Allergan Foundation, California Healthcare Institute, Chapman University, Cosmetic Surgery Foundation, Inc., University of California - Irvine School of Management

Stay informed and up-to-date on your network with RelSci news and business alerting service. Nurture your network and further your business goals with smart intelligence on the people and companies that matter most to you.

Browse in-depth profiles on 12 million influential people and organizations. Find RelSci relationships, employment history, board memberships, donations, awards, and more.

Explore notable alumni from top universities and organizations. Expand your fundraising pool and make warm introductions to potential new business connections.

Harness the power of your relationships with RelSci Pro, the powerful platform for identifying relationship-driven business opportunities and connections that can propel your career forward.

Stay informed and up-to-date on your network with RelSci news and business alerting service. Nurture your network and further your business goals with smart intelligence on the people and companies that matter most to you.

Browse in-depth profiles on 12 million influential people and organizations. Find RelSci relationships, employment history, board memberships, donations, awards, and more.

Explore notable alumni from top universities and organizations. Expand your fundraising pool and make warm introductions to potential new business connections.

Harness the power of your relationships with RelSci Pro, the powerful platform for identifying relationship-driven business opportunities and connections that can propel your career forward.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by David E. I. Pyott. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of David E. I. Pyott's profile does not indicate a business or promotional relationship of any kind between RelSci and David E. I. Pyott.